June 22, 2012
KENNESAW, Ga.Deerland Enzymes Inc. hosted congressman Phil Gingrey for a tour of its GMP (good manufacturing practice)-certified facility on May 29, 2012. Gingrey met with the company's executives to discuss their concerns over the current tax policy as well as FDA's NDI Draft Guidance for Industry.
Deerland Enzymes executives shared concerns over the effect current tax policy has on capital investment, job creation and export opportunities. Discussion also focused on the FDAs Draft Guidance for Industry, Dietary Supplements: New Dietary Ingredients Notifications and Related Issues." Deerland Enzymes executives shared with congressman Gingrey their hope that the FDAs revised Guidance document would clarify and facilitate the process used for new dietary supplement product innovation. However," said Scott Ravech, Deerland Enzymes CEO, FDAs approach more closely mirrors that of food additive regulations, which will be an additional obstacle to innovation and the introduction of new products, without any meaningful benefit to consumers."
You May Also Like
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023
More bioavailable hyaluronic acid complex for today’s beauty-from-within consumer – snapshotSep 18, 2023